Skip to main content
An official website of the United States government
Email

About the RPT Dosimetry Interest Group

External radiation therapy employs advanced imaging and sophisticated treatment planning systems to arrive at optimal dose distribution. In this way it provides the best treatment for each patient. Similarly, appropriate assessment of the radiation dose deposited in the tumor and normal tissues is crucial for the success of targeted radiopharmaceutical therapies (RPT). Advances in imaging and biodistribution science make new approaches to RPT treatment planning possible. By administering the radionuclide dose, either pre-therapeutic (diagnostic) or the first therapeutic fraction of the cycle, and determining the patient's residence time (a measure of how long the radionuclide is retained in the body), the total therapeutic dose can be precisely adjusted to maximize the therapeutic effect and minimize toxicity. To offer the best possible treatment, prospective treatment planning should be performed, and a patient-specific maximally tolerated therapeutic radiation dose should be used. Furthermore, dosimetry should be performed on a regular basis throughout the treatment.

Goals

  1. To develop standard operation procedures (SOPs) for RPT dosimetry
  2. To support dosimetry for RPT Clinical Trials.
  3. To ultimately make RPT a dosimetry-based curative treatment approach

Current Chairperson

Emille Roncali, Ph.D., UC Davis, eroncali@ucdavis.edu 

Telecommunications Schedule

The RPT Dosimetry Interest Group meets virtually via the Webex platform quarterly – on the 2nd Monday of March, June, September, and December at 3 p.m. ET.

Activities and Accomplishments

Access SOP's for dosimetry of Lu-177 and Ra-223 that have been developed for implementation in clinical trials through IROC & CIRO.

Interested in becoming a member of the RPT Dosimetry Interest Group?

Please Contact the Interest Group Coordinator:

Jacek Capala, Ph.D.
Radiation Research Program National Cancer Institute
Division of Cancer Treatment & Diagnosis
Tel: 240-276-5706
Email: jacek.capala@nih.gov

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “About the RPT Dosimetry Interest Group was originally published by the National Cancer Institute.”

Email